Actively Recruiting
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
Led by Mirador Therapeutics, Inc. · Updated on 2026-02-25
70
Participants Needed
1
Research Sites
58 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
CONDITIONS
Official Title
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants between 19 and 55 years of age (inclusive) at the time of signing informed consent.
- Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile, with official documentation at least 6 months prior to first dose.
- Male subjects must use highly effective contraception during sexual intercourse with female partners of childbearing potential; non-vasectomized males must use condoms with chemical barrier.
- Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to first dose.
- Good general health.
- Able to provide written informed consent and comply with study requirements.
You will not qualify if you...
- History or presence of any clinically significant organ system disease.
- Abnormal laboratory assessments, physical exam, or ECG outside normal range judged clinically significant.
- History of alcohol or drug abuse within past 24 months.
- Current use or history of regular tobacco or nicotine products within 3 months prior to screening.
- Use of any prescription drug within 21 days or 5 half-lives (whichever longer) before study drug; or OTC drug within 7 days or 5 half-lives before study drug.
- Use of any investigational drug or device within 30 days before first dose.
- Blood donation within 60 days or plasma donation within 14 days before dosing.
- Sensitivity or allergy to study drugs or their components that contraindicates participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mirador Clinical Department
San Diego, California, United States, 92121
Actively Recruiting
Research Team
T
Toll-Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here